אורלן- ANAGENESE 25+ קרם עיניים ישראל - עברית - Ministry of Health

אורלן- anagenese 25+ קרם עיניים

אפריל רשת חנויות בעמ - שיפור מראה העור

general sperm analysis kit ישראל - עברית - Ministry of Health

general sperm analysis kit

dyn bioshaf ltd. - מומחה - ערכה לבדיקה כללית של תאי זרע

general purpose drainage catheteres ישראל - עברית - Ministry of Health

general purpose drainage catheteres

עינת מדיקל סוכנויות בע"מ - רופא - קטטרים לניקוזים

פליקסוטייד נבולס 0.5 מג2 מל ישראל - עברית - Ministry of Health

פליקסוטייד נבולס 0.5 מג2 מל

glaxo smith kline (israel) ltd - fluticasone propionate - תרחיף לשאיפה לערפול - fluticasone propionate 0.5 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.children and adolescents from 4 to 16 years of age:treatment of acute exacerbations of asthma.

פליקסוטייד נבולס 2 מג2 מל ישראל - עברית - Ministry of Health

פליקסוטייד נבולס 2 מג2 מל

glaxo smith kline (israel) ltd - fluticasone propionate - תרחיף לשאיפה לערפול - fluticasone propionate 2 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.

Surgical products for General&Gynecological Surgery) ישראל - עברית - Ministry of Health

surgical products for general&gynecological surgery)

נאופרם ציוד רפואי ומסחר 1997 בע"מ - רופא

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob